Welcome !


Search Community

PEDS Reports and Data Tools



Postby Dr. Solona Danako » December 2nd, 2021, 4:04 am

“We are pleased to have advanced ARCT-032 as a novel mRNA-based development candidate for CF Lung Disease. ARCT-032, based on our proprietary LUNAR® technology, is designed to result in the efficient expression of a functional Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein in the lungs. We believe that ARCT-032 has the potential to address the root cause of CF lung disease, which is caused by the defective, or missing, CFTR protein,” said Pad Chivukula, Ph.D. Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. “While there has been progress with the recent approval of drugs for CF, many patients remain underserved. ARCT-032 has the potential to provide benefit to all CF patients, regardless of their underlying genetic mutations.”

Dr. Solona Danako
Posts: 392

Return to PEDS Reports and Data Tools

  • In total there are 4 users online :: 0 registered, 0 hidden and 4 guests (based on users active over the past 5 minutes)
  • Most users ever online was 583 on January 15th, 2020, 9:38 am
  • Users browsing this forum: No registered users and 4 guests